ProBioGen has announced the closing of a DirectedLuck Transposase Technology research license agreement with another global biopharma company
ProBioGen has announced the closing of a DirectedLuck Transposase Technology research license agreement with another global biopharma company. The license covers the evaluation of the DirectedLuck Transposase technology in their cell line development processes.
DirectedLuck builds on a transposase's principle but with additional major improvements. It has been optimised to recognise specific chromatin marks, guiding the transgene to genomic regions with highest transcriptional activity, which ensures exceptionally high protein expression and maximum stability.
The clone pools generated within days to weeks are highly representative of later clones. This reduces time and hands-on lab work for selecting superior clones for best titers, proven stability and product quality.
The DirectedLuck Transposase is compatible with additional genetic elements in standard expression vector design and can be used with any host cell line from different species and tissue origin. DirectedLuck has been applied to develop cell lines for standard mAbs, complex glycoproteins and bispecifics and is also applicable beyond protein and virus production in cell therapy.
DirectedLuck is available for out-licensing. Furthermore, ProBioGen applies DirectedLuck as a standard tool in clients' service projects at no extra charge.